New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

The Lupin stock has underperformed most of its peers over the past year on the back of muted performance in the first half of the year, delay in product launches, regulatory issues related to its facilities and higher valuations. While a 38 per cent return for the stock over the past year is better than the benchmark BSE Sensex return of 16 per cent it is way short of the peer index (BSE Healthcare) return of over 53 per cent. 

Going ahead, analysts believe that the stock has multiple triggers led by specialty products in the US market, India business,